Glytec’s Software Yields Superior Patient Outcomes According to Four New Studies in Journal of Diabetes Science and Technology

JANUARY 23, 2018

Glytec’s Software Yields Superior Patient Outcomes According to Four New Studies in Journal of Diabetes Science and Technology

Safety and efficacy of Glytec’s eGlycemic Management System® for diabetes therapy management, and its advantages over conventional methods, is further validated by four peer-reviewed studies.

Waltham, MA — Four new studies published in the January 2018 issue of Journal of Diabetes Science and Technology  (JDST) demonstrate superior patient outcomes and organizational performance with Glytec’s eGlycemic Management System® (eGMS®) versus conventional, paper-based protocols. In all instances, which included both inpatient and outpatient settings, use of eGMS® for diabetes and insulin therapy management was observed to be safer and more effective than ‘usual care,’ with lower rates of hypoglycemia, faster resolution of diabetic ketoacidosis (DKA), expedited time to target glucose, and sustained reductions in A1c. Additionally, use of eGMS® led to substantive efficiency gains in provider workflows, fewer point-of-care tests, shorter lengths of stay, and full adoption of best practices, including 96% utilization of basal bolus insulin.

Highlights of the four studies follow (click any title to access the full manuscript):

    • 21% faster resolution of metabolic ketoacidosis (bicarbonate level > 18 mmol/L) using eGMS®: 13.6 vs 17.3 hours.
    • 93% reduction in severe hypoglycemia (blood glucose < 40 mg/dL) using eGMS®: 0.46% vs 6.6% patients.
    • 29% (1.3 days) shorter average length of stay using eGMS®: 3.2 vs 4.5 days.
    • 99% reduction in severe hypoglycemia (blood glucose < 40 mg/dL) using eGMS®: 0.01% vs 5.4% patient days.
    • 94% decrease in hypoglycemia (blood glucose < 70 mg/dL) using eGMS®: 1.3% vs 21.5% patient days.
    • 51% increase in the amount of time spent within the target glucose range (110-180 mg/dL) using eGMS®: 63.7% vs 31.5% patient days.
    • 2,434 fewer hypoglycemic events and 40,589 fewer hyperglycemic events using eGMS®.
    • 37% (3.18 days) shorter average length of stay using eGMS®: 5.51 days vs 8.69 days.
    • 47% decrease in the number of point-of-care blood glucose tests using eGMS®: 26.8 vs 50.9 tests per patient.
    • Growth in utilization of basal bolus insulin from 5% to 96% using eGMS®.
    • 91% less time spent on daily insulin titration per prescriber per patient using eGMS® versus manual basal bolus protocols: 20.2 seconds vs 219.7 seconds.
    • 3.1% absolute decrease in A1c over 12 months: baseline average of 10.3% to 7.8% at three months, 7.8% at six months, 7.8% at nine months and 7.2% at 12 months.
    • Median of seven days for patients to reach their prescribed glucose goal (three consecutive days with average daily blood glucose < 180 mg/dL).
    • Number of severe hypoglycemic events (blood glucose < 40 mg/dL) at 0.05%: 18 of 36,315 blood glucose values.

Raymie McFarland, Vice President of Quality Initiatives at Glytec, says: “It’s a great privilege to have worked with so many clinicians who are passionate about improving glycemic management in and out of the hospital, and are willing to do the hard work that research studies like these entail. It’s also a great privilege to have these studies published in the Journal of Diabetes Science and Technology, whose editor-in-chief, Dr. David Klonoff, has created a truly one-of-a-kind medium for advancing the research of diabetes technologies.”

About Glytec

Founded in 2006, Glytec is the pioneer of personalized digital therapeutics. The company’s patented and FDA-cleared software-as-a-medical-device solutions improve the safety and health of people with diabetes and make insulin a more effective medication option for the millions unable to achieve their treatment goals. Glytec combines evidence-based decision support technologies with expert clinical services to optimize basal and bolus insulin therapies in the hospital and at home, and reduce hypoglycemia and other complications as well as avoidable ED visits, hospitalizations, readmissions and drug waste. The company has offices in Waltham, Massachusetts and Greenville, South Carolina. For more information visit

View on Business Wire